CADD-57. THE EFFICACY OF THERAPY WITH ABT-414, AN EGFR-TARGETING ADC, IS POTENTIALLY ALTERED BY HETEROZYGOUS DELETION OF THE ENDOCYTIC TRAFFICKING REGULATOR RBSN

Therapy with ABT-414 (depatux-m), a humanized monoclonal antibody drug conjugate (ADC) directed toward EGFRvIII and activated wild-type EGFR linked to MMAF, has demonstrated promising clinical activity in glioblastoma (GBM) patients with amplified EGFR and is currently being evaluated in clinical trials in first-line GBM disease settings. However, not all patients with amplified EGFR respond to ABT-414 and the reason is unclear. Cancer stem-like...